Farabi Pharmaceutical (XTEH:DFRB1) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Farabi Pharmaceutical Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.


Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.